Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available

ELITE PHARMACEUTICALS INC /NV/

ANDA submitted to FDA for generic version of an undisclosed anticoagulant drug product.
IQVIA reports branded product sales of $26 billion for twelve months ending March 2026.
No generic product currently on market; brand has unexpired patents and exclusivity in FDA Orange Book.
FDA approval and commercialization subject to successful filing, approval, and addressing patents.
Elite expands pipeline into high-value anticoagulant market; no timeline for launch provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.